Cargando…

Mycobacterium abscessus Associated Peritonitis with CAPD Successfully Treated Using a Linezolid and Tedizolid Containing Regimen Suggested Immunomodulatory Effects

Patient: Female, 38-year-old Final Diagnosis: Peritonitis Symptoms: Abdominal and/or epigastric pain Medication:— Clinical Procedure: — Specialty: Infectious Diseases OBJECTIVE: Rare disease BACKGROUND: Mycobacterium abscessus is one of the most important mycobacteria, but its associated peritonitis...

Descripción completa

Detalles Bibliográficos
Autores principales: Seki, Masafumi, Kamioka, Yasuhiro, Takano, Kazuki, Imai, Haruka, Shoji, Mai, Hariu, Maya, Oikawa, Nozomi, Kabutoya, Yukari, Watanabe, Yuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347031/
https://www.ncbi.nlm.nih.gov/pubmed/32598338
http://dx.doi.org/10.12659/AJCR.924642
_version_ 1783556516557619200
author Seki, Masafumi
Kamioka, Yasuhiro
Takano, Kazuki
Imai, Haruka
Shoji, Mai
Hariu, Maya
Oikawa, Nozomi
Kabutoya, Yukari
Watanabe, Yuji
author_facet Seki, Masafumi
Kamioka, Yasuhiro
Takano, Kazuki
Imai, Haruka
Shoji, Mai
Hariu, Maya
Oikawa, Nozomi
Kabutoya, Yukari
Watanabe, Yuji
author_sort Seki, Masafumi
collection PubMed
description Patient: Female, 38-year-old Final Diagnosis: Peritonitis Symptoms: Abdominal and/or epigastric pain Medication:— Clinical Procedure: — Specialty: Infectious Diseases OBJECTIVE: Rare disease BACKGROUND: Mycobacterium abscessus is one of the most important mycobacteria, but its associated peritonitis in patients on continuous ambulatory peritoneal dialysis (CAPD) appears relative rare, and the treatment regimen of the antibiotics are still unclear. CASE REPORT: A 38-year-old female with chronic glomerulonephritis on CAPD who was diagnosed with M. abscessus-associated peritonitis. Symptoms exacerbated despite treatment with a 3-antibiotic regimen combining clarithromycin, imipenem/cilastatin (IPM/CS), and minocycline (MINO). However, after changing IPM/CS and MINO to linezolid (LZD), her condition and inflammation improved, and she was able to be maintained on oral tedizolid (TZD). CONCLUSIONS: Oxazolidinones such as LZD and TZD might be candidate antibiotics for the treatment of M. abscessus-associated diseases with chronic renal failure due to their immunomodulatory effects and non-renal excretion.
format Online
Article
Text
id pubmed-7347031
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-73470312020-07-14 Mycobacterium abscessus Associated Peritonitis with CAPD Successfully Treated Using a Linezolid and Tedizolid Containing Regimen Suggested Immunomodulatory Effects Seki, Masafumi Kamioka, Yasuhiro Takano, Kazuki Imai, Haruka Shoji, Mai Hariu, Maya Oikawa, Nozomi Kabutoya, Yukari Watanabe, Yuji Am J Case Rep Articles Patient: Female, 38-year-old Final Diagnosis: Peritonitis Symptoms: Abdominal and/or epigastric pain Medication:— Clinical Procedure: — Specialty: Infectious Diseases OBJECTIVE: Rare disease BACKGROUND: Mycobacterium abscessus is one of the most important mycobacteria, but its associated peritonitis in patients on continuous ambulatory peritoneal dialysis (CAPD) appears relative rare, and the treatment regimen of the antibiotics are still unclear. CASE REPORT: A 38-year-old female with chronic glomerulonephritis on CAPD who was diagnosed with M. abscessus-associated peritonitis. Symptoms exacerbated despite treatment with a 3-antibiotic regimen combining clarithromycin, imipenem/cilastatin (IPM/CS), and minocycline (MINO). However, after changing IPM/CS and MINO to linezolid (LZD), her condition and inflammation improved, and she was able to be maintained on oral tedizolid (TZD). CONCLUSIONS: Oxazolidinones such as LZD and TZD might be candidate antibiotics for the treatment of M. abscessus-associated diseases with chronic renal failure due to their immunomodulatory effects and non-renal excretion. International Scientific Literature, Inc. 2020-06-29 /pmc/articles/PMC7347031/ /pubmed/32598338 http://dx.doi.org/10.12659/AJCR.924642 Text en © Am J Case Rep, 2020 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Articles
Seki, Masafumi
Kamioka, Yasuhiro
Takano, Kazuki
Imai, Haruka
Shoji, Mai
Hariu, Maya
Oikawa, Nozomi
Kabutoya, Yukari
Watanabe, Yuji
Mycobacterium abscessus Associated Peritonitis with CAPD Successfully Treated Using a Linezolid and Tedizolid Containing Regimen Suggested Immunomodulatory Effects
title Mycobacterium abscessus Associated Peritonitis with CAPD Successfully Treated Using a Linezolid and Tedizolid Containing Regimen Suggested Immunomodulatory Effects
title_full Mycobacterium abscessus Associated Peritonitis with CAPD Successfully Treated Using a Linezolid and Tedizolid Containing Regimen Suggested Immunomodulatory Effects
title_fullStr Mycobacterium abscessus Associated Peritonitis with CAPD Successfully Treated Using a Linezolid and Tedizolid Containing Regimen Suggested Immunomodulatory Effects
title_full_unstemmed Mycobacterium abscessus Associated Peritonitis with CAPD Successfully Treated Using a Linezolid and Tedizolid Containing Regimen Suggested Immunomodulatory Effects
title_short Mycobacterium abscessus Associated Peritonitis with CAPD Successfully Treated Using a Linezolid and Tedizolid Containing Regimen Suggested Immunomodulatory Effects
title_sort mycobacterium abscessus associated peritonitis with capd successfully treated using a linezolid and tedizolid containing regimen suggested immunomodulatory effects
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7347031/
https://www.ncbi.nlm.nih.gov/pubmed/32598338
http://dx.doi.org/10.12659/AJCR.924642
work_keys_str_mv AT sekimasafumi mycobacteriumabscessusassociatedperitonitiswithcapdsuccessfullytreatedusingalinezolidandtedizolidcontainingregimensuggestedimmunomodulatoryeffects
AT kamiokayasuhiro mycobacteriumabscessusassociatedperitonitiswithcapdsuccessfullytreatedusingalinezolidandtedizolidcontainingregimensuggestedimmunomodulatoryeffects
AT takanokazuki mycobacteriumabscessusassociatedperitonitiswithcapdsuccessfullytreatedusingalinezolidandtedizolidcontainingregimensuggestedimmunomodulatoryeffects
AT imaiharuka mycobacteriumabscessusassociatedperitonitiswithcapdsuccessfullytreatedusingalinezolidandtedizolidcontainingregimensuggestedimmunomodulatoryeffects
AT shojimai mycobacteriumabscessusassociatedperitonitiswithcapdsuccessfullytreatedusingalinezolidandtedizolidcontainingregimensuggestedimmunomodulatoryeffects
AT hariumaya mycobacteriumabscessusassociatedperitonitiswithcapdsuccessfullytreatedusingalinezolidandtedizolidcontainingregimensuggestedimmunomodulatoryeffects
AT oikawanozomi mycobacteriumabscessusassociatedperitonitiswithcapdsuccessfullytreatedusingalinezolidandtedizolidcontainingregimensuggestedimmunomodulatoryeffects
AT kabutoyayukari mycobacteriumabscessusassociatedperitonitiswithcapdsuccessfullytreatedusingalinezolidandtedizolidcontainingregimensuggestedimmunomodulatoryeffects
AT watanabeyuji mycobacteriumabscessusassociatedperitonitiswithcapdsuccessfullytreatedusingalinezolidandtedizolidcontainingregimensuggestedimmunomodulatoryeffects